the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

Woyach Jennifer A.; Guinn Daphne; Ruppert Amy S.; Blachly James S.; Lozanski Arletta; Heerema Nyla A.; Zhao Weiqiang; Coleman Joshua; Jones Daniel; Abruzzo Lynne V.; Gordon Amber; Mantel Rose; Smith Lisa L.; McWhorter Samantha; Davis Melanie; Doong Tzyy-Jye; Ny Fan; Lucas Margaret S.; Chase Weihong; Jones Jeffrey; Flynn Joseph M.; Maddocks Kami J.; Jaglowski Samantha; Andritsos Leslie A.; Awan Farrukh T.; Blum Kristie; Grever Michael R.; Lozanski Gerard; Byrd John C.; Johnson Amy J.

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

【24h】

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

机译：CLL患者在依鲁替尼治疗期间耐药亚克隆的形成和扩增之前复发

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology 》 |2016年第22期| 共5页
作者
Woyach Jennifer A.; Guinn Daphne; Ruppert Amy S.; Blachly James S.; Lozanski Arletta; Heerema Nyla A.; Zhao Weiqiang; Coleman Joshua; Jones Daniel; Abruzzo Lynne V.; Gordon Amber; Mantel Rose; Smith Lisa L.; McWhorter Samantha; Davis Melanie; Doong Tzyy-Jye; Ny Fan; Lucas Margaret S.; Chase Weihong; Jones Jeffrey; Flynn Joseph M.; Maddocks Kami J.; Jaglowski Samantha; Andritsos Leslie A.; Awan Farrukh T.; Blum Kristie; Grever Michael R.; Lozanski Gerard; Byrd John C.; Johnson Amy J.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL [J] . Woyach Jennifer A., Guinn Daphne, Ruppert Amy S., Blood: The Journal of the American Society of Hematology . 2016 ,第22期

机译：CLL患者在依鲁替尼治疗期间耐药亚克隆的形成和扩增之前复发
2. Outcomes of Ibrutinib Therapy Given after Prior Venetoclax Therapy in Ibrutinib-Naive Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) [J] . Brown Jennifer R., Davids Matthew S., Chang Julie, Blood: The Journal of the American Society of Hematology . 2018 ,第NovaelaTreatmentAppr期

机译：在伊布勒替尼 - 幼稚患者的复发/耐火（R / R）慢性淋巴细胞白血病（CLL）后伊布勒替尼氏菌治疗后伊布洛替尼治疗疗法的结果
3. UKCLL Forum analysis of patient outcomes post-ibrutinib therapy for relapsed/refractory CLL UK CLL Forum [J] . Leukemia and lymphoma . 2020 ,第S1期

机译：UKCLL论坛分析患者结果后Ibrutinib疗法复发/难治性CLL UK CLL论坛
4. Efficiency and Toxmcity of the Fludarabine and Cyclo- Phosphamide Combined Therapy in Relapsed/ Resistant Patients with B-cell Chronic Lymphocytic Leukaemia (CLL)-Polish Multicenter Study [C] . M. Kowal, A. Dmoszynska, D. Jawniak, European Haematology Association . 2002

机译：B-Cell慢性淋巴细胞白血病（CLL） - 渗透多中心研究的复发/抗性患者复发/抗性患者的氟氮胺碱和环磷酰胺联合治疗的效率和毒性
5. Kinase Targeting Therapies in Chronic Lymphocytic Leukemia: Mechanisms of Acquired Ibrutinib Resistance and the Pre-Clinical Development of OSU-T315. [D] . Liu, Ta-Ming. 2014

机译：激酶靶向疗法在慢性淋巴细胞性白血病中：获得性依鲁替尼耐药性的机制和OSU-T315的临床前开发。
6. Protocol description of the HOVON 141/VISION trial: a prospective multicentre randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations [O] . Mark-David Levin, Arnon P Kater, Mattias Mattsson, 2020

机译：霍恩141 / Vision试验的协议描述：肌酐清除患者患者的伊布勒替尼患者的前瞻性多期随机期II试验≥30ml/ min≥30ml/ min患有或没有TP53的耐火慢性淋巴细胞白血病（RR-CLL）像差距
7. Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations [O] . Mark-David Levin, Arnon Kater, Mattias Mattsson, 2020

机译：霍恩141 / Vision试验的协议描述：肌酐清除患者患者的伊布勒替尼患者的前瞻性多期，随机期II试验≥30ml/ min，≥30ml/ min，患有或没有TP53的耐火慢性淋巴细胞白血病（RR-CLL）像差距

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

著录项

相似文献

相关主题

期刊订阅